Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EBT (2020 - 2022)

Atea Pharmaceuticals has reported EBT over the past 3 years, most recently at -$34.3 million for Q4 2022.

  • Quarterly results put EBT at -$34.3 million for Q4 2022, down 128.3% from a year ago — trailing twelve months through Dec 2022 was -$119.5 million (down 186.22% YoY), and the annual figure for FY2025 was -$164.5 million, up 1.76%.
  • EBT for Q4 2022 was -$34.3 million at Atea Pharmaceuticals, down from -$11.9 million in the prior quarter.
  • Over the last five years, EBT for AVIR hit a ceiling of $121.2 million in Q4 2021 and a floor of -$42.1 million in Q1 2022.
  • Median EBT over the past 3 years was -$10.9 million (2020), compared with a mean of $678666.7.
  • Biggest five-year swings in EBT: skyrocketed 870.14% in 2021 and later crashed 457.19% in 2022.
  • Atea Pharmaceuticals' EBT stood at $20.7 million in 2020, then surged by 486.91% to $121.2 million in 2021, then plummeted by 128.3% to -$34.3 million in 2022.
  • The last three reported values for EBT were -$34.3 million (Q4 2022), -$11.9 million (Q3 2022), and -$31.2 million (Q2 2022) per Business Quant data.